{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:24:46Z","timestamp":1793042686745,"version":"4.5.0"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,6,22]],"date-time":"2011-06-22T00:00:00Z","timestamp":1308700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pigment Cell Melanoma Res"],"published-print":{"date-parts":[[2011,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The effect of <jats:italic>NRAS<\/jats:italic> mutations on the pathological features and clinical outcomes in patients with cutaneous melanoma was compared with that of tumors containing <jats:italic>BRAF<\/jats:italic><jats:sup>V600E<\/jats:sup> mutations and tumors wild type for both (WT). Clinical outcome data were obtained from a prospective cohort of 249 patients. Mutations involving <jats:italic>NRAS<\/jats:italic> and <jats:italic>BRAF<\/jats:italic><jats:sup>V600E<\/jats:sup> were detected by PCR and were sequence verified. Cox proportional hazards regression was performed to relate <jats:italic>NRAS<\/jats:italic> and <jats:italic>BRAF<\/jats:italic> mutations to clinical outcome. Seventy\u2010five percentage of <jats:italic>NRAS<\/jats:italic> mutations occurred in tumors &gt;1\u2003mm thick (<jats:italic>BRAF<\/jats:italic><jats:sup>V600E<\/jats:sup> 40%, WT 34%); 75% of <jats:italic>NRAS<\/jats:italic> mutations had &gt;1 mitosis\/mm<jats:sup>2<\/jats:sup> (<jats:italic>BRAF<\/jats:italic><jats:sup>V600E<\/jats:sup> 40%, WT 55%). When compared to WT, multivariate analysis of melanoma\u2010specific survival (MSS) identified <jats:italic>NRAS<\/jats:italic> mutations as an adverse prognostic factor [hazard ratio (HR) 2.96; P\u2003=\u20030.04] but not <jats:italic>BRAF<\/jats:italic><jats:sup>V600E<\/jats:sup> mutations (HR 1.73; P\u2003=\u20030.23). <jats:italic>NRAS<\/jats:italic> mutations were associated with thicker tumors and higher rates of mitosis when compared to <jats:italic>BRAF<\/jats:italic><jats:sup>V600E<\/jats:sup> and WT melanoma and independently of this, with shorter MSS.<\/jats:p>","DOI":"10.1111\/j.1755-148x.2011.00873.x","type":"journal-article","created":{"date-parts":[[2011,5,26]],"date-time":"2011-05-26T16:35:28Z","timestamp":1306427728000},"page":"666-672","source":"Crossref","is-referenced-by-count":222,"title":["Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma"],"prefix":"10.1111","volume":"24","author":[{"given":"Bianca","family":"Devitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Salemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin\u2010Yuan","family":"Tzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dobrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,6,22]]},"reference":[{"key":"e_1_2_8_2_1","article-title":"Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): preliminary report of the PHAMOUS study","volume":"28","author":"Aitkens M.B.","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23788.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.9001","article-title":"A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT","volume":"27","author":"Carvajal R.D.","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_8_5_1","unstructured":"COSMIC database. (2010).Catalogue of somatic mutations in cancer http:\/\/www.sanger.ac.uk\/genetics\/CGP\/cosmic\/"},{"key":"e_1_2_8_6_1","first-page":"CD001215","article-title":"Systemic treatments for metastatic cutaneous melanoma","author":"Crosby T.","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050092"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.356"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1985"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cmr.0000232300.22032.86"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2276"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002011"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700026"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2010.00671.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08833"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20481"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00376.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.8597","article-title":"Effect of mutational status on response, PFS, or OS after treatment with IL\u20102 for metastatic melanoma","volume":"28","author":"Joseph R.W.","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_8_19_1","first-page":"3362","article-title":"BRAF mutations in metastatic melanoma: a possible association with clinical outcome","volume":"9","author":"Kumar R.","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1127515"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700632"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.521"},{"key":"e_1_2_8_23_1","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt K.","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.2.74"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0248-4900(01)01125-X"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1054"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/370527a0"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1169-3"},{"key":"e_1_2_8_29_1","first-page":"1800","article-title":"Relative reciprocity of NRAS and PTEN\/MMAC1 alterations in cutaneous melanoma cell lines","volume":"60","author":"Tsao H.","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000236"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwk052"}],"container-title":["Pigment Cell &amp; Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-148X.2011.00873.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-148X.2011.00873.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T10:42:01Z","timestamp":1697280121000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-148X.2011.00873.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,22]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["10.1111\/j.1755-148X.2011.00873.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-148x.2011.00873.x","archive":["Portico"],"relation":{},"ISSN":["1755-1471","1755-148X"],"issn-type":[{"value":"1755-1471","type":"print"},{"value":"1755-148X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,22]]}}}